Best of ASCO - 2014 Annual Meeting



Attend this session at the
2019 ASCO Annual Meeting!

Session: Genitourinary (Prostate) Cancer

Type: Poster Session

Time: Saturday June 1, 1:15 PM to 4:15 PM

Location: Hall A

Session: Genitourinary (Prostate) Cancer

Type: Poster Discussion Session

Time: Saturday June 1, 4:30 PM to 6:00 PM

Location: Arie Crown Theater

Prospective head-to-head comparative phase 3 study between 18F-fluciclovine and 68Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.


Genitourinary (Prostate) Cancer

2019 ASCO Annual Meeting

Abstract No:

Poster Board Number:
Poster Discussion Session (Board #126)

J Clin Oncol 37, 2019 (suppl; abstr 5014)

Author(s): Jeremie Calais, Francesco Ceci, Matthias Eiber, Tore Bach-Gansmo, Cristina Nanni, Bital Savir-Baruch, Michael Hofman, Tom Hope, Christoph Rischpler, David Elashoff, Tristan Grogan, Magnus Dahlbom, Roger Slavik, Jeannine Gartmann, Robert Evan Reiter, Matthew Rettig, Hossein Jadvar, Wolfgang P Fendler, Johannes Czernin; UCLA, Los Angeles, CA; University of Turin, Turin, Italy; Rechts der Isar University Hospital, Technical University of Munich, Munich, Germany; Oslo University Hospital, Oslo, Norway; Bologna University School of Medicine, Bologna, Italy; Loyola University Medical Center, Maywood, IL; Peter MacCallum Cancer Centre, Melbourne, Australia; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Essen, Essen, Germany; University of California Los Angeles, Los Angeles, CA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Institute of Urologic Oncology, University of California, Los Angeles, Los Angeles, CA; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; University of Southern California, Los Angeles, CA

Abstract Disclosures


Background: This is a prospective single-center, single-arm, head-to-head phase 3 study of paired 18F-fluciclovine (FACBC) and 68Ga-PSMA-11 (PSMA) PET/CT scans for localizing early biochemical recurrence (BCR) of prostate cancer (PCa) after radical prostatectomy (RP) (NCT02940262). Methods: Fifty consecutive patients with BCR and prostate specific antigen (PSA) levels ranging from ≥0.2 to ≤2.0 ng/mL without any prior salvage therapy were included. All patients underwent FACBC and PSMA PET/CT scans within ≤15 days. PET/CT scans were each interpreted by 3 independent blinded expert readers not involved in study design and data acquisition. Region consensus interpretation (T,N,M1a,M1b,M1c) was generated based on majority rule in cases of reader disagreement (2 vs 1). PET/CT scans were considered as positive if any region was rated as positive. Detection rates per-patient and per-region served as primary study endpoint. Results: Median time interval between the 2 scans was 6 days (range 1-15). Median PSA level at the time of imaging was 0.50 ng/ml (mean 0.63; range 0.2-2.0 ng/ml). The detection rates were significantly lower with FACBC than with PSMA PET/CT per-patient (26% vs 56%; p = 0.003) and per-region for pelvic nodes (N) (8% vs 30%; p = 0.003) or any extra-pelvic lesions (M) (0% vs 16%; p = 0.008). Reader agreement for PSMA PET/CT image interpretations was significantly higher than for FACBC PET/CT (0.67 vs 0.20; p = 0.015). Conclusions: In patients with BCR and low serum PSA levels after RP, PSMA PET/CT demonstrates higher detection rates and superior reader agreement when compared with FACBC PET/CT. Therefore, PSMA PET/CT should be the imaging modality of choice in patients with early BCR. Clinical trial information: NCT03515577

Other Abstracts in this Sub-Category:


1. Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 5076 First Author: Neeraj Agarwal
Category: Genitourinary (Prostate) Cancer - Local-Regional


2. Assessment of 2,000 patients presenting to a multidisciplinary prostate cancer clinic in the United Kingdom.

Meeting: 2019 ASCO Annual Meeting Abstract No: 5077 First Author: Pandora Rudd
Category: Genitourinary (Prostate) Cancer - Local-Regional


3. Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis.

Meeting: 2019 ASCO Annual Meeting Abstract No: 5078 First Author: Amado J. Zurita
Category: Genitourinary (Prostate) Cancer - Local-Regional